20 Best Biotech Stocks Under $20 to Buy Now

7. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 31

Stock Price: $13.82

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is positioned seventh on our list.

TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while maintaining a Neutral rating. The firm updated its model following the FDA’s lifting of the clinical hold on the Nex-z hATTR-PN trial.

Similarly, on the same day, H.C. Wainwright analyst Mitchell Kapoor also raised the price target on Intellia Therapeutics, Inc. (NASDAQ:NTLA) to $25 from $15 and maintained a Buy rating. The firm noted that the FDA’s decision to lift the clinical hold indicates Nex-Z’s risks are manageable, though the market continues to price in “an existential threat,” and also increased its probability of approval for Nex-Z to 35% from 25%.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical‑stage biotechnology company pioneering CRISPR‑based gene editing therapies to treat serious genetic diseases. The company uses its proprietary in vivo and ex vivo platforms and develops precision treatments aimed at providing durable, curative solutions, advancing multiple programs toward clinical impact while expanding the potential of gene editing.